These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 21852502

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
    White AL, Dou L, Chan HT, Field VL, Mockridge CI, Moss K, Williams EL, Booth SG, French RR, Potter EA, Butts C, Al-Shamkhani A, Cragg MS, Verbeek JS, Johnson PW, Glennie MJ, Beers SA.
    J Immunol; 2014 Aug 15; 193(4):1828-35. PubMed ID: 25024386
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
    Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV.
    Cancer Cell; 2016 Jun 13; 29(6):820-831. PubMed ID: 27265505
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
    Liu X, Zhao Y, Shi H, Zhang Y, Yin X, Liu M, Zhang H, He Y, Lu B, Jin T, Li F.
    Nat Commun; 2019 Sep 27; 10(1):4206. PubMed ID: 31562320
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D, Goldberg MV, Chiu ML.
    J Biol Chem; 2016 Dec 30; 291(53):27134-27146. PubMed ID: 27856634
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.
    Li F, Ravetch JV.
    Proc Natl Acad Sci U S A; 2013 Nov 26; 110(48):19501-6. PubMed ID: 24218606
    [Abstract] [Full Text] [Related]

  • 14. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA, Towers TL, Presta LG, Ravetch JV.
    Nat Med; 2000 Apr 26; 6(4):443-6. PubMed ID: 10742152
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.
    White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.
    J Immunol; 2011 Aug 15; 187(4):1754-63. PubMed ID: 21742972
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
    Knorr DA, Dahan R, Ravetch JV.
    Proc Natl Acad Sci U S A; 2018 Oct 23; 115(43):11048-11053. PubMed ID: 30297432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.